Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011854 (
type 1 diabetes
)
20,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The costimulatory molecule CD226 is highly expressed on effector/memory T cells and natural killer cells. Costimulatory signals received by T cells can impact both central and peripheral tolerance mechanisms. Genetic polymorphisms in
CD226
have been associated with susceptibility to
type 1 diabetes
and other autoimmune diseases. We hypothesized that genetic deletion of
Cd226
in the non-obese diabetic (NOD) mouse would impact
type 1 diabetes
incidence by altering T cell activation. CD226 knockout (KO) NOD mice displayed decreased disease incidence and insulitis in comparison to wild-type (WT) controls. Although female CD226 KO mice had similar levels of sialoadenitis as WT controls, male CD226 KO mice showed protection from
dacryoadenitis
. Moreover, CD226 KO T cells were less capable of adoptively transferring disease compared to WT NOD T cells. Of note, CD226 KO mice demonstrated increased CD8
+
single positive (SP) thymocytes, leading to increased numbers of CD8
+
T cells in the spleen. Decreased percentages of memory CD8
+
CD44
+
CD62L
-
T cells were observed in the pancreatic lymph nodes of CD226 KO mice. Intriguingly, CD8
+
T cells in CD226 KO mice showed decreased islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP)-tetramer and CD5 staining, suggesting reduced T cell receptor affinity for this immunodominant antigen. These data support an important role for CD226 in
type 1 diabetes
development by modulating thymic T cell selection as well as impacting peripheral memory/effector CD8
+
T cell activation and function.
...
PMID:CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation. 3301 15